FACTORS DETERMINING THE DEVELOPMENT OF GALLSTONES AND PANCREATITIS IN PATIENTS USING TIRZEPATIDE
DOI:
https://doi.org/10.63330/aurumpub.036-016Keywords:
Tirzepatide, Gallstones, Pancreatitis, GLP-1, Cholelithiasis, Metabolic adverse effectsAbstract
Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has demonstrated high efficacy in glycemic control and weight reduction. However, adverse effects related to the biliary and pancreatic tracts have been observed, including gallstones, cholecystitis, and acute pancreatitis. This article critically analyzes the pathophysiological, clinical, and metabolic factors associated with these complications, highlighting risks, probable mechanisms, and predisposing variables.
Downloads
References
FRIAS, J. P. et al. Efficacy and safety of tirzepatide versus placebo as add-on therapy to insulin in patients with type 2 diabetes (SURPASS-5). The Lancet, London, v. 398, n. 10300, p. 595-604, 2021.
JASTREBOFF, A. M. et al. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, Boston, v. 387, n. 3, p. 205-216, 2022.
LUDVIK, B. et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in type 2 diabetes (SURPASS- 3). The Lancet, London, v. 398, n. 10300, p. 583-598, 2021.
SINGH, S. et al. Glucagon-like peptide 1–based therapies and risk of gallbladder and biliary diseases: systematic review and meta-analysis. JAMA Internal Medicine, Chicago, v. 177, n. 11, p. 1-10, 2017.
SMITS, M. M.; VAN RAAIJ, E. P.; TACK, C. J. The role of GLP-1 receptor agonists in gallbladder motility and bile composition. Diabetes, Obesity and Metabolism, Oxford, v. 18, n. 4, p. 339-348, 2016.
BONORA, B. M. et al. Glucagon-like peptide-1 receptor agonists and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, Amsterdam, v. 128, p. 136-144, 2017.
NAU, C. K. et al. Rapid weight loss and risk of gallstone formation: pathophysiology and clinical implications. World Journal of Gastroenterology, Beijing, v. 19, n. 42, p. 1-8, 2013.
PORTINCASA, P. et al. Gallstone disease: pathophysiology and clinical management. Journal of Gastroenterology and Hepatology, Oxford, v. 31, n. 1, p. 1- 10, 2016.
ELASHOFF, M. et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology, Philadelphia, v. 141, n. 1, p. 150- 156, 2011.
ROSENSTOCK, J. et al. Once-weekly tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2). The New England Journal of Medicine, Boston, v. 385, n. 6, p. 503-515, 2021.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
